S?ntese de compostos cumar?nicos-1,2,3-triaz?is an?logos ao Novobiocin planejados como inibidores da HSP90

• Ano de defesa: 2015
• Autor(a) principal: Franco, Daiana de Fatima Portella
• Orientador(a): K?mmerle, Arthur Eugen
• Banca de defesa: K?mmerle, Arthur Eugen, Lacerda, Renata Barbosa, Pinheiro, S?rgio
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal Rural do Rio de Janeiro
• Programa de Pós-Graduação: Programa de P?s-Gradua??o em Qu?mica
• Departamento: Instituto de Ci?ncias Exatas
• País: Brasil
• Palavras-chave em Português: C?ncer; HSP90; Novobiocin; [1,2,3]-triaz?is
• Palavras-chave em Inglês: cancer; HSP90; Novobiocin; [1,2,3]-triazoles
• Área do conhecimento CNPq: Qu?mica
• Link de acesso: https://tede.ufrrj.br/jspui/handle/jspui/1875

Cancer is a generic term related to more than 100 types of diseases which resemble each other by their disorganized cellular growth. HSP90 are ATP-dependent chaperones responsible for the activation and stabilization of more than 200 proteins. Most of these proteins are connected to cancer and need HSP90 to execute their activities. Thus, HSP90 inhibitors may indirect inhibit plenty oncogenic proteins. According to the literature, there are N-terminal and C-terminal domains, nevertheless, C-terminal inhibitors present more advantages. Then, the advancement of C-terminal inhibitors represents an applicable alternative and an intense field of study. Novobiocin is the first compound identified as C-terminal domain inhibitor. Nowadays, Novobiocin analogues have been synthesized, besides its structure-activity relationship elucidated in order to develop more potents analogues. For that reason, the goal of this project is to obtain 2 analogue series of Novobiocin. The scheme of these series was based on maintaining the coumaniric part presented on Novobiocin: isosteric replacement of the amide group that binds coumarin to the 4-hydroxy-3-(3-methylbut-2-yl)-benzamide, by the [1,2,3]-triazole; and exploration of methyl groups (AN1) and hydroxyl (AN2) in substitution of subunit noviose. AN1 series (76a-g) and AN2 (77a-g) were synthesized from the followed reactions: 7-hydroxy-coumarine o-methylation (83); 7-methoxy-coumarine 3-bromation (82); Sonogashira cross-coupling from 3-bromo-7-R-coumarine (81a-b); 7-R-3-((trimethylsilyl)ethynyl-coumarine trimethylsilyl deprotection (88a-b); and lastly, synthesis of the triazole ring, through cicloaddition reaction, 1,3-dipolar catalysed by copper (CuAAc), using 3-ethynyl-7-R-coumarine (80a-b) and aromatic azides. It is worth taking into consideration that 3-bromo-7-R-coumarine (81b) was obtained from the key compound, 3-bromo-7-R-methoxy-coumarine (81a) by o-demethylation reaction. 12 compounds were obtained (76a-g) and 8 of them (76a-b, 77d) were nicely purified and then, characterized by spectroscopic techniques (IR, 1H and 13C NMR). The ?one-pot? synthesis of 7-methoxy-3-(1H-1,2,3-triazole-4-phenyl)-coumarine 76b from 88a compound (Yield=86%) was more efficient than the one realized in two steps (global yield=47,2%). Results are potential and satisfactory, moreover there is no citation in any literature about biological activities of the synthesized compounds. Continuing this work, the pure compounds (76a-b, 77d) will be tested on breast cancer cell lines SkBr3 and MCF-7.